Morgan Stanley Reiterates Overweight on Royalty Pharma, Maintains $52 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has reiterated an Overweight rating on Royalty Pharma (NASDAQ:RPRX) and maintained a $52 price target.
July 11, 2023 | 1:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on Royalty Pharma and maintained a $52 price target, indicating a positive outlook for the company.
The reiteration of an Overweight rating by Morgan Stanley indicates a positive outlook for Royalty Pharma. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100